BILL NUMBER: SJR 9	ENROLLED
	BILL TEXT

	ADOPTED IN SENATE  SEPTEMBER 11, 2015
	ADOPTED IN ASSEMBLY  SEPTEMBER 10, 2015
	AMENDED IN ASSEMBLY  SEPTEMBER 10, 2015
	AMENDED IN SENATE  JUNE 29, 2015

INTRODUCED BY   Senator Stone
   (Coauthors: Senators Bates, Fuller, Huff, Morrell, Nguyen, Runner,
and Vidak)
   (Coauthors: Assembly Members Achadjian, Alejo, Travis Allen,
Atkins, Baker, Bigelow, Bloom, Bonilla, Bonta, Brown, Burke,
Calderon, Campos, Chang, Chau, Chávez, Chiu, Chu, Cooper, Dababneh,
Dahle, Daly, Dodd, Eggman, Frazier, Gallagher, Cristina Garcia,
Eduardo Garcia, Gatto, Gipson, Gomez, Gonzalez, Gordon, Hadley,
Jones, Jones-Sawyer, Kim, Lackey, Levine, Linder, Lopez, Low, Mathis,
Mayes, McCarty, Medina, Mullin, Nazarian, Obernolte, O'Donnell,
Olsen, Perea, Quirk, Rendon, Rodriguez, Salas, Santiago, Mark Stone,
Thurmond, Ting, Wagner, Waldron, Weber, Wilk, Williams, and Wood)

                        MAY 22, 2015

   Relative to the Chronic Kidney Disease Improvement in Research and
Treatment Act of 2015.


	LEGISLATIVE COUNSEL'S DIGEST


   SJR 9, Stone. The Chronic Kidney Disease Improvement in Research
and Treatment Act of 2015.
   This measure would urge the President and the Congress of the
United States to enact the Chronic Kidney Disease Improvement in
Research and Treatment Act of 2015.



   WHEREAS, Approximately 50 years ago, kidney failure was a death
sentence; and
   WHEREAS, In 1972, Congress developed the Medicare End-Stage Renal
Disease benefit. In doing so, Congress ensured that regardless of age
or income, any American would have access to lifesaving dialysis
care. That was the turning point in kidney care; and
   WHEREAS, The Chronic Kidney Disease Improvement in Research and
Treatment Act of 2015 (HR 1130) was introduced in the House of
Representatives by Representative Tom Marino to address kidney
disease care; and
   WHEREAS, House Resolution 1130 is built on three primary tenets.
First, for individuals living with chronic diseases, especially when
those diseases are complicated by multiple comorbid conditions,
coordinated care is key to improving outcomes and lowering health
care costs. Second, increased research can lead to a deeper
understanding of kidney disease prevention and ultimately to
significant innovations in treatment. Lastly, stability in the
Medicare Program is central to an end-stage renal disease program
that ensures quality and produces optimal results; and
   WHEREAS, If left untreated, chronic kidney disease can progress to
kidney failure, also known as end-stage renal disease, and early
cardiovascular death; and
   WHEREAS, More than 20 million adults in the United States, or more
than 10 percent of the adult population, are estimated to have
chronic kidney disease and most are undiagnosed; and
   WHEREAS, Kidney disease is the ninth leading cause of death in the
United States; and
   WHEREAS, In the United States, diabetes and high blood pressure
are the leading causes of kidney failure, accounting for 72 percent
or about three out of four new cases of kidney failure; and
   WHEREAS, The number of kidney failure cases in the United States
population has more than tripled since 1990 and is expected to grow
because of an aging population and the increasing number of people
with conditions, such as diabetes and high blood pressure, that place
them at the risk of developing chronic kidney disease; now,
therefore, be it
   Resolved by the Senate and the Assembly of the State of
California, jointly, That the Legislature urges the President and the
Congress of the United States to enact the Chronic Kidney Disease
Improvement in Research and Treatment Act of 2015 (HR 1130); and be
it further
   Resolved, That the Secretary of the Senate transmit copies of this
resolution to the President of the United States, to each Senator
and Representative from California in the Congress of the United
States, and to the author for appropriate distribution.